Suppr超能文献

痰液蛋白质中的溴酪氨酸以及特布他林和布地奈德在哮喘治疗中的效果

Bromotyrosines in sputum proteins and treatment effects of terbutaline and budesonide in asthma.

作者信息

van Dalen Christine J, Aldridge Ruth E, Chan Timothy, Senthilmohan Revathy, Hancox Robert J, Cowan Jan O, Taylor D Robin, Town G Ian, Kettle Anthony J

机构信息

Centre for Public Health Research, Massey University, Wellington, New Zealand.

出版信息

Ann Allergy Asthma Immunol. 2009 Oct;103(4):348-53. doi: 10.1016/S1081-1206(10)60536-4.

Abstract

BACKGROUND

Inhaled corticosteroids are widely used in the treatment of persistent asthma, usually combined with inhaled beta2-agonists. Previous research suggests that short-acting beta2-agonists (SABAs) may downregulate the anti-inflammatory effects of inhaled corticosteroids, thereby increasing asthma morbidity.

OBJECTIVE

To determine whether 3-bromotyrosine and 3,5-dibromotyrosine levels, specific markers of eosinophil activation, reflect treatment effects on airway inflammation of inhaled corticosteroids and SABAs and support previous conclusions.

METHODS

Levels of 3-bromotyrosine and 3,5-dibromotyrosine were measured in sputum supernatants using stable isotope dilution gas chromatography-mass spectrometry in a randomized, placebo-controlled, crossover study of treatment with terbutaline, budesonide, and their combination in patients with persistent asthma. Thirty-four individuals were randomized, and 28 completed the study.

RESULTS

Treatment with budesonide lowered median 3-bromotyrosine levels compared with treatment with placebo, terbutaline, and budesonide-terbutaline (0.24 vs 0.64, 0.62, and 0.43 3-bromotyosine/tyrosine [mmol/mol]; P < .05) and lowered median 3,5-dibromotyrosine levels compared with placebo and terbutaline treatments (0.04 vs 0.11 and 0.07 3,5-dibromotyrosine/ tyrosine [mmol/mol], P < .05). Unlike eosinophil numbers, 3-bromotyrosine and 3,5-dibromotyrosine levels did not increase with terbutaline treatment compared with placebo treatment but were significantly raised when terbutaline was added to budesonide treatment. 3-Bromotyrosine levels correlated significantly with eosinophil cationic protein levels in all groups.

CONCLUSIONS

3-Bromotyrosine and 3,5-dibromotyrosine levels reflect treatment effects in asthma and support previous findings that SABAs impair the anti-inflammatory effects of inhaled corticosteroids. In addition to eosinophil numbers and eosinophil cationic protein levels, these modified tyrosine residues provide useful information about the inflammatory state of the airways.

摘要

背景

吸入性糖皮质激素广泛用于治疗持续性哮喘,通常与吸入性β2受体激动剂联合使用。先前的研究表明,短效β2受体激动剂(SABAs)可能会下调吸入性糖皮质激素的抗炎作用,从而增加哮喘发病率。

目的

确定嗜酸性粒细胞活化的特异性标志物3-溴酪氨酸和3,5-二溴酪氨酸水平是否反映吸入性糖皮质激素和SABAs对气道炎症的治疗效果,并支持先前的结论。

方法

在一项随机、安慰剂对照、交叉研究中,使用稳定同位素稀释气相色谱-质谱法测量持续性哮喘患者痰液上清液中3-溴酪氨酸和3,5-二溴酪氨酸的水平,该研究使用特布他林、布地奈德及其组合进行治疗。34名个体被随机分组,28名完成了研究。

结果

与安慰剂、特布他林和布地奈德-特布他林治疗相比,布地奈德治疗降低了3-溴酪氨酸的中位数水平(0.24对0.64、0.62和0.43 3-溴酪氨酸/酪氨酸[mmol/mol];P<.05),与安慰剂和特布他林治疗相比,降低了3,5-二溴酪氨酸的中位数水平(0.04对0.11和0.07 3,5-二溴酪氨酸/酪氨酸[mmol/mol],P<.05)。与嗜酸性粒细胞数量不同,与安慰剂治疗相比,特布他林治疗时3-溴酪氨酸和3,5-二溴酪氨酸水平没有增加,但当特布他林添加到布地奈德治疗中时显著升高。在所有组中,3-溴酪氨酸水平与嗜酸性粒细胞阳离子蛋白水平显著相关。

结论

3-溴酪氨酸和3,5-二溴酪氨酸水平反映了哮喘的治疗效果,并支持先前的发现,即SABAs会损害吸入性糖皮质激素的抗炎作用。除了嗜酸性粒细胞数量和嗜酸性粒细胞阳离子蛋白水平外,这些修饰的酪氨酸残基还提供了有关气道炎症状态的有用信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验